Investigational · Not FDA-approved · Not offered by REMEVi
Retatrutide is an investigational once-weekly injection from Eli Lilly that activates three receptors: GIP, GLP-1 and glucagon. In the phase 3 TRIUMPH-1 trial its highest dose produced 28.3% average weight loss at 80 weeks. It is not FDA-approved, not prescribable in the US, and REMEVi does not offer it.
Trial results, not REMEVi averages; individual results vary.
For compounded semaglutide or tirzepatide — not retatrutide. No card to start.
Ver en Español§ 01 · What it is
01 / 06Retatrutide (development code LY3437943) is an investigational molecule from Eli Lilly and Company. Lilly’s own medical site states that retatrutide activates the GIP, GLP-1 and glucagon receptors — three receptors, against two for tirzepatide and one for semaglutide.
Lilly puts it this way:
“Retatrutide is an investigational molecule and is not currently approved in any countries or geographies.”
Eli Lilly Medical — mechanism of action, accessed September 9, 2026
It is given as a once-weekly injection inside clinical trials. There is no approved product, no authorised label, no pharmacy stock and no lawful compounded version. That is why this page carries no dosing information of any kind: there is no dose a reader could lawfully obtain or give themselves.
§ 02 · Trials
02 / 06One phase 2 study published in the New England Journal of Medicine and four phase 3 trials from the TRIUMPH programme have reported results as of September 2026. Every figure below travels with its trial, its duration and its source, inside the same card.
−28.3%
TRIUMPH-1 · 80 weeks
In the phase 3 TRIUMPH-1 trial, 2,339 participants were randomised. At the highest dose studied, average weight loss was 28.3% at 80 weeks, and 45.3% of participants reached at least 30% weight loss. A 104-week extension subset of 532 participants averaged 30.3%.
Trial results, not REMEVi averages; individual results vary.
−28.7%
TRIUMPH-4 · 68 weeks
TRIUMPH-4 studied adults with obesity or overweight and knee osteoarthritis. At the highest dose studied, weight loss reached up to 28.7% of body weight at 68 weeks, and the WOMAC pain score fell by up to 4.5 points. Discontinuation for adverse events was 18.2% at that dose against 4.0% on placebo.
Trial results, not REMEVi averages; individual results vary.
Eli Lilly press release — TRIUMPH-4 results, December 11, 2025
−20.8%
TRIUMPH-2 · duration not stated in the release
TRIUMPH-2 studied adults with type 2 diabetes and obesity or overweight. At the highest dose studied, average weight loss was 20.8%, alongside a 1.5% reduction in A1C. Lilly’s release states 80 weeks for TRIUMPH-3 but does not state a duration for this figure, so we do not supply one.
Trial results, not REMEVi averages; individual results vary.
−22.6%
TRIUMPH-3 · 80 weeks
TRIUMPH-3 studied adults with obesity and cardiovascular disease. At the highest dose studied, average weight loss was 22.6% at 80 weeks.
Trial results, not REMEVi averages; individual results vary.
−24.2%
Phase 2 (NEJM, 2023) · 48 weeks
The 48-week phase 2 trial published in the New England Journal of Medicine enrolled 338 adults with obesity. At the highest dose studied, the least-squares mean change in body weight was −24.2% at 48 weeks, against −2.1% on placebo.
Trial results, not REMEVi averages; individual results vary.
These are separate trials with different designs, populations and durations — not head-to-head comparisons. Trial results, not REMEVi averages; individual results vary.
The figures above are from trials of the investigational molecule, in the populations each trial enrolled. They are not REMEVi averages and they do not describe what any individual person achieves.
§ 03 · Safety
03 / 06The effects below are the ones each trial’s own publication or release reported, attributed to that trial and to the highest dose it studied. They are not aggregated across trials and they are not compared with any other medication.
The New England Journal of Medicine phase 2 report states that the most common adverse events were gastrointestinal, that they were dose-related, and that they were mostly mild to moderate in severity.
Trial results, not REMEVi averages; individual results vary.
The same report describes dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter. No trial publication we located reports a cardiac rhythm signal beyond that observation.
Trial results, not REMEVi averages; individual results vary.
At the highest dose studied in TRIUMPH-1, nausea was reported by 42.4% of participants against 14.8% on placebo, and diarrhea by 32.0% against 13.5% on placebo.
Trial results, not REMEVi averages; individual results vary.
In TRIUMPH-4, 18.2% of participants at the highest dose studied stopped treatment because of adverse events, against 4.0% on placebo. The most common adverse events reported at that dose were nausea (43.2%), diarrhea (33.1%), constipation (25.0%) and vomiting (20.9%).
Trial results, not REMEVi averages; individual results vary.
Eli Lilly press release — TRIUMPH-4 results, December 11, 2025
Across both trials Lilly reported diarrhea in 24–34% of participants, nausea in 14–28%, constipation in 15–18% and decreased appetite in 3–17%, describing these events as generally mild to moderate with the majority resolving during treatment.
Trial results, not REMEVi averages; individual results vary.
We located no trial publication reporting a cardiac rhythm signal beyond the dose-dependent heart-rate increase described above. We state nothing stronger than that, because no source supports it.
§ 04 · Status
04 / 06No. As of September 2026 retatrutide is not FDA-approved, and no application for approval has been submitted. In its July 23, 2026 release Lilly stated that it plans to submit a Biologics License Application to FDA in the first quarter of 2027 — a plan to file, not an approval and not a date of availability.
“Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027”
The full page on regulatory status, what the FDA says about compounded retatrutide and why no list price exists is here:
§ 05 · Access
05 / 06No, other than as a clinical-trial participant. That is the only lawful route in the United States today. The registered TRIUMPH trials are listed below exactly as Lilly publishes them, each with its ClinicalTrials.gov link; we do not run them, we do not recruit for them, and we do not know which are enrolling.
Registered retatrutide trials (source: Lilly Medical)
Eli Lilly Medical — the registered retatrutide trials, page last reviewed February 11, 2026
And on compounded preparations, the FDA puts it this way:
“Retatrutide and cagrilintide cannot be used in compounding under federal law.”
“These are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
FDA warning letter naming compounded retatrutide (MARCS-CMS 715883), September 9, 2025
REMEVi does not offer retatrutide, none of our partner pharmacies prepare it, and there is nothing to order here. What our licensed providers do prescribe is in the next section.
§ What you can get
06 / 06Two molecules that are FDA-approved as brand products and available as a compounded preparation on a licensed provider’s prescription after an online evaluation. The price is published, it is the same at every dose, and it does not go up.
Semaglutide from $159/mo on the 24-week plan — $169/mo on the 12-week plan, $199/mo month-to-month. The same price at every dose, all-inclusive.
In STEP 1 (NEJM, 2021), semaglutide 2.4 mg weekly produced a mean body-weight change of −14.9% at 68 weeks, against −2.4% on placebo.
Trial results, not REMEVi averages; individual results vary.
Everything about compounded semaglutideTirzepatide from $225/mo on the 24-week plan — $233/mo on the 12-week plan, $269/mo month-to-month. The same price at every dose, all-inclusive.
In SURMOUNT-1 (NEJM, 2022), tirzepatide 15 mg weekly produced a mean body-weight reduction of −20.9% at 72 weeks, on the treatment-regimen estimand.
Trial results, not REMEVi averages; individual results vary.
Everything about compounded tirzepatideThat price includes
a licensed provider visit · the medication · cold-chain shipping · monthly follow-up · the portal and a care coordinator in English or Spanish
No membership fee · cancel any time · refund if a provider doesn't approve you.
And to check us
Semaglutide is the medication in Ozempic® and Wegovy®; tirzepatide is the medication in Mounjaro® and Zepbound®. Those are FDA-approved products of Novo Nordisk and Eli Lilly; REMEVi is not affiliated with either company. A compounded preparation from a state-licensed US 503A pharmacy is not FDA-approved and is not a generic version of any of them.
§ FAQ
05 entriesIt is a peptide-based investigational drug: a synthetic peptide that binds three receptors. That describes its chemistry, not its availability — it is not approved, it is not prescribable in the US, and REMEVi does not offer it.
No. REMEVi’s licensed providers prescribe compounded semaglutide and compounded tirzepatide. We do not prescribe retatrutide, we do not sell it, and none of the pharmacies we work with prepare it.
No. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, and on September 9, 2025 it issued a warning letter describing compounded retatrutide products as unapproved new drugs and misbranded drugs. The full quotations and their links are in the access section above.
Nobody can say. Lilly stated in July 2026 that it plans to submit a Biologics License Application to FDA in the first quarter of 2027. That is a plan to file, not an approval and not a date of availability. We publish no date beyond what Lilly itself has said.
No se han publicado datos de subgrupo hispano/latino para la retatrutida (verificado el 9 de septiembre de 2026). Ni el estudio de fase 2 del New England Journal of Medicine ni los comunicados de fase 3 de Lilly reportan resultados específicos por origen hispano o latino. No inferimos esos resultados a partir de los datos de la población general: si se publican, lo diremos aquí.
§ Sources
Primary sources only: peer-reviewed journals, the FDA, and Eli Lilly’s own medical and investor sites. If a figure is not in this list, it is not on the page.
REMEVi does not offer retatrutide. What our licensed providers do prescribe is compounded semaglutide and compounded tirzepatide, with the price published on this site before you give us anything. The secure intake takes about 2 minutes, no card to start, in English or Spanish.
